Jubilant Pharma and Aavis Pharmaceuticals announce the launch of Hydroxychloroquine Sulfate Tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the US market. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma.
Hydroxychloroquine Sulfate tablets are indicated for the treatment of Malaria, Lupus, Erythematosus, and Rheumatoid Arthritis. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the US through our marketing partner,” stated Ashok Barot, chairman, Aavis Pharmaceuticals. “Our team is doing their best to fulfil the current surge in demand. We will continue our efforts to be a significant and reliable supplier of this product,” stated Swapnil Shah, managing director, Senores Pharmaceuticals, R&D partner, and an affiliate of Aavis Pharmaceuticals.
“We are excited about this launch,” stated Pramod Yadav, chief executive officer, Jubilant Pharma. “We are pleased to partner with Aavis to create access for the growing demand for this product and expand our basket of offerings in the US market,” he added.
According to IQVIA MAT June 2020 report, the US annual market size for Hydroxychloroquine Sulfate Tablets, 200 mg, was approximately US$237 million.
Based in Atlanta, Georgia, Aavis Pharmaceuticals is one of the fastest-growing pharmaceutical companies in the US market. Currently, the company has more than 12 products commercially launched or filed with the USFDA.
Senores Pharmaceuticals is an Ahmedabad, India based R&D partner and an affiliate of Aavis Pharmaceuticals. It is involved in product development and marketing in the USA and ROW markets.
Jubilant Pharma (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Life Sciences, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products, and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of over 49 radio pharmacies in the US. The Company has a team of around 5,200 multicultural people worldwide and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a ‘Partner of Choice’ by leading pharmaceutical companies globally.
